$7.49
0.669.66%
Last update: Nov 6, 4:00 PM
Oculis Holding AG (OCS) Stock Price, Quote, News & History
OCSNASDAQ
Oculis (OCS) stock plummets 37% after its Phase 3 DIAMOND trials for diabetic macular edema fail to meet the primary endpoint.
You can purchase shares of Oculis Holding (NASDAQ:OCS) through any online brokerage.
Other companies in Oculis Holding’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Oculis Holding has a consensus price target of $37.90.
The stock price for Oculis Holding (NASDAQ: OCS) is $7.49 last updated November 6, 2026 at 4:00 PM EST.
There are no upcoming dividends for Oculis Holding.
Oculis Holding does not have any upcoming earnings scheduled.
There is no upcoming split for Oculis Holding.
Oculis Holding is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED);...
